Trastuzumab related to slight increase in cardiac events

Shafer, Emily
April 2008
Hem/Onc Today;4/25/2008, Vol. 9 Issue 7, p25
The article discusses research on the role of the drug Trastuzumab in cardiac events. It references a study by Edith Perez, MD and colleagues, wherein 2,992 patients were evaluated after being given medication including trastuzumab. Findings show that posttreatment cardiac events, which include congestive heart failure and cardiac death, were higher in patients who were given trastuzumab, by less than 4%. Researchers say that the incidence of cardiac toxicity is minimal to discourage the use of trastuzumub for treatment.


Related Articles

  • Relations of the Congestive Cardiac Failure with Troponin I and CK-MB. Topal, Fatih Esat; Oguzturk, Hakan; Topal, Firdevs; Turtay, Muhammet Gökhan; Yıldırιm, Birdal // HealthMed;2012, Vol. 6 Issue 2, p643 

    The cardiac failure is a disease of a significant increase in incidence within the last two decades. In Turkey, like many other countries, the cardiac failure is the main reason of many deaths. In this study, the major structural characteristic of Congestive Cardiac Failure (CCF) is the...

  • Trastuzumab Before Breast Surgery? Large Trial Says Yes But Does Not Quell Debate. Rowan, Karen // JNCI: Journal of the National Cancer Institute;4/1/2009, Vol. 101 Issue 7, p448 

    The article focuses on the advantages and disadvantages of trastuzumab during breast surgery. It says that several studies conducted on trastuzumab prove that when used along neoadjuvant and anthracycline-based chemotherapy, it can benefit patients and increased the event-free survival. It...

  • Cardiac Toxicity of Trastuzumab-Related Regimens in HER2-Overexpressing Breast Cancer. Ewer, Michael S.; O'Shaughnessy, Joyce A. // Clinical Cancer Update;Dec2007, Vol. 1 Issue 1, p22 

    The pivotal trial by Slamon and colleagues of trastuzumab combined with chemotherapy in metastatic breast cancer showed a high incidence of congestive heart failure (CHF) among patients who had received trastuzumab and anthracycline-based therapy simultaneously. As a result, the development of...

  • Acute doxorubicin cardiotoxicity is associated with miR-146a-induced inhibition of the neuregulin-ErbB pathway. Horie, Takahiro; Ono, Koh; Nishi, Hitoo; Nagao, Kazuya; Kinoshita, Minako; Watanabe, Shin; Kuwabara, Yasuhide; Nakashima, Yasuhiro; Takanabe-Mori, Rieko; Nishi, Eiichiro; Hasegawa, Koji; Kita, Toru; Kimura, Takeshi // Cardiovascular Research;Sep2010, Vol. 87 Issue 4, p656 

    Aims A significant increase in congestive heart failure (CHF) was reported when the anti-ErbB2 antibody trastuzumab was used in combination with the chemotherapy drug doxorubicin (Dox). The aim of the present study was to investigate the role(s) of miRNAs in acute Dox-induced cardiotoxicity....

  • A new era in CHF treatment may be near. Cerrato, Paull // RN;May97, Vol. 60 Issue 5, p81 

    Reports on the potential of the experimental drug carvedilol to treat congestive heart failure (CHF). Effectiveness in lowering CHF death rate.

  • Digoxin increases mortality among women with congestive heart failure. See, Sharon; Bruno, Patricio // Journal of Family Practice;Feb2003, Vol. 52 Issue 2, p106 

    The article presents a study that analyzes the sex-based differences of the effect of digoxin on mortality in the treatment of congestive heart failure. The subjects of the study were 6800 patients who had stable heart failure with an injection fraction of 45% or less and who were in normal...

  • The ABCs of Treating Congestive Heart Failure.  // American Family Physician;9/15/2001, Vol. 64 Issue 6, p936 

    Editorial. Introduces an article which summarized guidelines for treating congestive heart failure caused by systolic dysfunction, which appeared on the September 15, 2001 issue of `American Family Physician.'

  • Cardiovascular disease. Gore, Joel M.; Dalen, James E. // JAMA: Journal of the American Medical Association;6/19/96, Vol. 275 Issue 23, p1797 

    Focuses on advances in cardiovascular disease. Increased prevalence of chronic congestive heart failure which is due, partly, to improved survival resulting from medical therapy; Study of coronary artery revascularization; Cost of thrombolytic therapy for acute myocardial infarction; Efficacy...

  • Blocking aldosterone can reduce mortality in severe heart failure.  // Geriatrics;Jan99, Vol. 54 Issue 1, p60 

    Shows that adding spironolactone to standard therapy for severe congestive heart failure has life-saving benefits. Comments from Doctor Bertram Pitt; Results from a double-blind study; Background information on spironolactone.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics